These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7084415)

  • 1. The effect of L-dopa on pupillary diameter in mice.
    Korczyn AD; Keren O
    Experientia; 1982 Apr; 38(4):481-2. PubMed ID: 7084415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine and L-dopa: inhibition of thyrotropin-stimulated thyroidal thyroxine release.
    Maayan ML; Sellitto RV; Volpert EM
    Endocrinology; 1986 Feb; 118(2):632-6. PubMed ID: 2867890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
    Antonaccio MJ; Kerwin L
    J Pharmacol Exp Ther; 1976 Feb; 196(2):380-8. PubMed ID: 1255483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinstatement of vaginal cycles in aged female rats.
    Linnoila M; Cooper RL
    J Pharmacol Exp Ther; 1976 Nov; 199(2):477-82. PubMed ID: 988180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro occurrence of m-octopamine in the cultured cephalic ganglion of Locusta migratoria L. after L-dopa administration.
    Coulon JF; Lafon-Cazal M; David JC
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1984; 78(1):77-80. PubMed ID: 6146487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-Dopa inhibits prolactin secretion in proestrous rats.
    Wiggins JF; Fernstrom JD
    Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation by naloxone of the anti-oxotremorine effect of L-DOPA.
    Quock RM; Lucas TS
    Eur J Pharmacol; 1983 Nov; 95(3-4):193-8. PubMed ID: 6653670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 11. Central cardiovascular effects of L-DOPA and clonidine in the lizard, Agama caudospinosa.
    Johansson P
    Acta Physiol Scand; 1982 Sep; 116(1):37-40. PubMed ID: 7158390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salivary secretion induced by L-DOPA in haloperidol-treated rats.
    Pazo JH; Tumilasci OR; Medina JH; Dvorkin MA
    J Auton Nerv Syst; 1984 Sep; 11(2):173-9. PubMed ID: 6491157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the mechanism of hyperglycemia and stimulation of growth hormone secretion by L-dopa.
    Hampshire J; Moraru E; Altszuler N
    Pharmacology; 1978; 17(3):138-48. PubMed ID: 704657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locomotor stimulation by L-dopa: relative importance of noradrenaline receptor activation.
    Andén NE; Strömbom U; Svensson TH
    Psychopharmacology (Berl); 1977 Nov; 54(3):243-8. PubMed ID: 413140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol].
    Rochiccioli P; Enjaume P; Dutau G; Ribot C; Augier D
    Arch Fr Pediatr; 1976 Jan; 33(1):55-66. PubMed ID: 985031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.